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Abstract
Previous research in various species has shown that granulocyte-colony stimulating factor
stimulates the production and release of neutrophils from bone marrow. The objective of this
study was to characterize the effects of polyethylene glycol-bound bovine granulocyte col-
ony-stimulating factor (pegbovigrastim; Imrestor, Elanco) on circulating leukocyte counts.
Thirty-four Holstein cows were randomly assigned to receive 2 injections of either physio-
logic saline (n = 16) or pegbovigrastim (n = 18), 7 days before expected calving (d -7) and
within 24 hours after calving (d 0). Cows were sampled at d -7, d -6, d 0, d +1, d +7, and d
+21, relative to calving. Only cows for which the interval from the first injection to calving
was 4 d and 10 d were included, such that the interval (mean ± SD) from first treatment
to calving was 6.7 ± 1.9 d. Treatment effects were assessed with mixed linear regression
models. After the first injection, neutrophil counts (×109/ L) in pegbovigrastim-treated cows
increased from 4.3 (95% CI 3.8 to 4.8) at d -7 to 18.2 (CI 16.3 to 20.3) at d -6 (P < 0.0001).
Their counts then decreased from d -6 to d 0, when the second injection was administered,
at a rate of -0.31 ×109 neutrophils/L/day (P < 0.0001). After the second injection, neutrophil
counts increased from 16.4 (CI 13.7 to 19.6) at d 0 to 32.8 (CI 25.2 to 42.7) at d +1 (P <
0.0001), after which counts decreased at a rate of -3.73 ×109 neutrophils/L/day until d +7 (P <
0.0001). Counts continued to decrease from d +7 to d +21 at a slower rate of -0.43 ×109 neu-
trophils/L/day (P < 0.0001), until baseline levels were reached. Conversely, in control cows,
neutrophil counts were unchanged from d -7 to d -6 (P = 0.86) after the first injection and then
decreased from 6.1 (CI 5.0–7.3) at d 0, to 3.2 (CI 2.4–4.2) at d +1 (P < 0.0001) after the sec-
ond injection. Neutrophil count was greater (P < 0.001) in pegbovigrastim-treated than in con-
trol cows at days -6, 0, +1 and +7. Area under the curve (cells ×109/ L per 28 d) for neutrophil
counts in the pegbovigrastim group was 429, versus 99 in the control group (P < 0.0001).
The response to each injection of pegbovigrastim was additive and consisted of 95% seg-
mented neutrophils, suggesting that the effect of the treatment was to release mature neutro-
phils from a substantial pool available in the bone marrow. The sustained increase in
circulating neutrophil count around the time of calving may contribute to improved health dur-
ing the peripartum transition period.
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Introduction
During the periparturient period, dairy cows are at increased risk of metabolic disorders and
infectious disease. Diseases in early lactation, such as mastitis, retained placenta, and reproduc-
tive tract diseases can lead to high treatment costs, decreased milk production, and impaired
reproductive performance [1]. The well-documented negative energy balance (NEB) experi-
enced by dairy cows in early lactation contributes to a reduction in immune function and a
predisposition to disease. Uterine disorders and mastitis are associated with decreased neutro-
phil and lymphocyte function, which are in turn associated with decreased dry matter intake
(DMI) and a greater degree of NEB [2, 3]. Infection and inflammation trigger cytokines and
chemokines to direct the production and release of leukocytes from bone marrow and their
migration to the site of infection. Granulocyte colony-stimulating factor (G-CSF) is a growth
factor that stimulates the differentiation of hematopoietic stem cells to granulocytes [4]. Differ-
entiation and maturation from a myeloblast in the bone marrow to a neutrophil in circulation
is driven primarily by G-CSF [4]. Injection of G-CSF stimulates proliferation and increases the
number of mature neutrophils in circulation. Daily injections of recombinant bovine G-CSF
have been shown to significantly reduce immune suppression and neutropenia in dairy cattle
[5]. Covalently binding polyethylene glycol (PEG) to the recombinant bovine G-CSF protein
(PEG-rbG-CSF) produced increased numbers of neutrophils in circulation with increased
myeloperoxidase production for 10 to 14 days after injection [6]. Previous studies exploring
pegbovigrastim in dairy cows demonstrated increases in circulating neutrophil count and
function [7, 8], and a decrease in the incidence of clinical mastitis [9, 10] compared to control
cows. The objective of this study was to determine the effects of pegbovigrastim, a commer-
cially available form of PEG-rbG-CSF, on complete blood counts in peripheral circulation
when administered 7 days before anticipated calving and within 24 h after calving, according
to the product label. In particular, we wanted to evaluate leukocyte counts at both the time of
each injection and 24 h later and to characterize the response to each treatment. It was hypoth-
esized that compared to control cows, treated cows would have elevated neutrophil counts fol-
lowing injections.
Materials and methods
The study was designed as a double-blind, randomized controlled trial with two treatment
groups; the present data are a subset from a larger clinical trial. Thirty-four primiparous
(n = 15) and multiparous (n = 19) Holstein cows were enrolled in two high-producing com-
mercial dairy herds in Southern Ontario, Canada. Farm A contributed 19 cows (n = 10 pegbo-
vigrastim; n = 9 control) and Farm B, 15 cows (n = 8 pegbovigrastim; n = 7 control). All study
cows were housed in free-stall facilities, fed total mixed rations for ad libitum intake to meet
their nutrient requirements, had water available ad libitum, and were milked 3 times daily in a
parlour. The study was approved by the Animal Care Committee of University of Guelph,
Ontario, Canada (AUP # 3642). Cows were cared for in accordance to the Code of Practice for
the Care and Handling of Dairy Cattle (2009) and the farms were licensed and inspected by
provincial authorities for animal care every second year. Cows were enrolled weekly approxi-
mately 7 d before their expected calving date (272 to 279 d of gestation). Each cow was ran-
domly assigned to receive a 2.7 mL subcutaneous injection of either sterile physiological saline
(0.9% sodium chloride) or 15 mg of pegbovigrastim (Imrestor; Elanco, Ontario, Canada),
according to the label directions. Randomization was done formally with lists for each farm,
balancing treatment assignments in permuted blocks of 4 animals. Pre-labelled, pre-filled
study syringes identified only with a number were refrigerated (2–8˚C) until use. Therefore,
both investigators and farmers were blinded to treatment assignments. All cows received 2
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injections of their assigned treatment, the first administered one week before expected calving,
and the second within 24 h after calving. Samples were taken d -7 and d -6 relative to expected
parturition, then d 0, d +1, d +7, and d +21 relative to actual parturition. In accordance to the
product label that states the first dose may be administered 4 to 10 days before the anticipated
calving date, we only included cows for which the interval from the first injection to calving
fell within this range. Thus, the interval (mean ± SD) from first treatment to calving was
6.7 ± 1.9 d. Approximately 10 mL of blood was collected from the coccygeal vessels into evacu-
ated plastic tubes containing EDTA-K2. Whole blood samples were sent to the University of
Guelph Animal Health Laboratory (AHL) within 2 h of collection and were analysed using an
ADVIA 2120/2120i Hematology System machine differential (Siemens Healthcare Diagnostics
Inc., Deerfield, IL). The initial machine differential did not provide the number of band versus
segmented neutrophils. Therefore, to further describe the difference between the proportion
of band neutrophils and segmented mature neutrophils, a single blood sample was taken 1 d
after injection from 14 randomly selected cows. Each of these cows were treated with either
saline or pegbovigrastim as described above, but were separate to the 34 cows detailed below.
Samples were sent to the AHL within 1 h of collection and underwent an additional manual
differential leukocyte assessment.
Data can be found in S1 Dataset and all statistical analyses were performed using SAS soft-
ware, version 9.4 (SAS Institute Inc., Cary, NC, USA). Continuous outcomes were log10 trans-
formed if distribution analysis and Shapiro-Wilk’s test determined that they were not
normally distributed. The effect of pegbovigrastim on circulating blood counts was tested
using multilevel mixed linear regression models. Farm was included as a random effect and
time was considered a repeated effect, with individual cow as the model subject and an ante-
dependence covariance structure. The following variables were tested: treatment, time, parity,
body condition score (BCS) at enrollment, the interval between injections, and first-order
interactions with treatment. A significance level of α = 0.05 was used. Manual backward step-
wise elimination determined the fixed effects of the model. Because the main effects of treat-
ment and time were important variables of interest for this study, they were forced into each
model. Area under the curve (AUC) was calculated for each cow using the trapezoidal method
[11] and a mixed linear regression model with farm as a random effect was constructed to
compare the effect of treatment on neutrophil count AUC throughout the study.
Results
Neutrophil, monocyte, eosinophil, and basophil counts were not normally distributed, so were
log10 transformed. Results are reported as back-transformed least-squares means, with 95%
confidence intervals (CI). Detailed results are presented in Table 1. There were significant
interactions between treatment and time for neutrophil, lymphocyte, and eosinophil counts.
Treatment did not have a significant effect on red blood cell, monocyte, or basophil counts
(P = 0.34, P = 0.61, and P = 0.94 respectively), whereas time and parity did. Pre-partum BCS
and the interval between injections had no effect on any blood parameters and no interactions
with treatment (P> 0.2). All hematology counts were relatively constant throughout the study
for cows in the control group. Cows treated with pegbovigrastim had substantial, additive
increases in circulating neutrophil counts after each injection. Neutrophil counts in pegbovi-
grastim-treated cows were significantly higher than in control cows on d -6, d 0, d +1 and d
+7, (Fig 1) (P< 0.0001). After the first injection, neutrophil counts (×109/ L) in pegbovigras-
tim-treated cows significantly increased from 4.3 (CI 3.8–4.8) at d -7 to 18.2 (CI 16.3–20.3) at
d -6 (P< 0.0001). Their counts then decreased significantly from d -6 to d 0, when the second
injection was administered, at a rate of -0.31 ×109 neutrophils/L/day (P< 0.0001). After the
Pegbovigrastim in dairy cattle
PLOS ONE | https://doi.org/10.1371/journal.pone.0198701 June 28, 2018 3 / 8
second injection, neutrophil counts increased from 16.4 (CI 13.7–19.6) at d 0 to 32.8 (CI 25.2–
42.7) at d +1 (P< 0.0001), after which counts decreased at a rate of -3.73 ×109 neutrophils/L/
day until d +7 (P< 0.0001). Counts continued to decrease from d +7 to d +21 at a slower rate
of -0.43 ×109 neutrophils/L/day (P< 0.0001), until baseline levels were reached. Conversely, in
control cows, neutrophil counts were unchanged from d -7 to d -6 (P = 0.86) after the first
injection and then decreased from 6.1 (CI 5.0–7.3) at d 0, to 3.2 (CI 2.4–4.2) at d +1 (P<
0.0001) after the second injection. The AUC (cells ×109/ L per 28 d) for neutrophil counts in
the pegbovigrastim-treated group was 429, versus 99 in the control group (P< 0.0001). In the
separate group of cows with the manual differential leukocyte assessment, those in the control
group (n = 5) had no band cells detected, with 100% segmented neutrophils. On average in the
pegbovigrastim group (n = 9), band cells represented 5% (ranging from 1.3% to 9.6%) of the
total neutrophil count, with the rest being segmented mature neutrophils.
Discussion
This study is the first to report neutrophil counts at both the time of injection and the response
24 h following each injection of pegbovigrastim. Cows that received pegbovigrastim had signif-
icant, marked increases in neutrophil counts of approximately 15 ×109/L, 24 h after each injec-
tion. The increased neutrophil count was expected, because G-CSF is a growth factor related
specifically to neutrophil differentiation [4]. Cows were able to sustain the elevated count after
Table 1. Effect of pegbovigrastim treatment on circulating leukocyte counts in periparturient dairy cattle at various sample times.
Sample time (days from calving) P- Value
-7 -6 0 1 7 21 Treatment Time Treatment × Time Parity
Leukocyte
Type
Treatment
Group
Mean (95% Confidence Interval)
Neutrophils Control 4.01 4.05 6.06 3.20 2.15 3.29 <0.0001 <0.0001 <0.0001 0.0001
(× 109 /L) (n = 16) (3.51–
4.58)
(3.60–4.55) (5.01–7.34) (2.42–4.23) (1.57–
2.96)
(2.65–
4.09)
Pegbovigrastim 4.28 18.21 16.36 32.80 10.39 4.37
(n = 18) (3.77–
4.84)
(16.30–
20.33)
(13.66–
19.58)
(25.22–
42.66)
(7.70–
14.02)
(3.56–
5.36)
P value 0.46 <0.0001 <0.0001 <0.0001 <0.0001 0.05
Lymphocytes Control 2.97 2.68 2.45 2.61 2.73 2.63 0.04 <0.0001 0.04 <0.0001
(× 109 /L) (n = 16) (2.16–
3.78)
(1.81–3.54) (1.61–3.29) (1.73–3.50) (1.90–
3.56)
(1.79–
3.47)
Pegbovigrastim 2.77 1.67 2.32 2.39 2.20 2.71
(n = 18) (1.97–
3.57)
(0.92–2.52) (1.29–3.15) (1.52–3.25) (1.38–
3.02)
(1.88–
3.53)
P value 0.41 0.002 0.66 0.51 0.05 0.78
Eosinophils Control 0.25 0.25 0.16 0.17 0.12 0.2 0.0001 <0.0001 0.001 0.48
(× 109 /L) (n = 16) (0.19–
0.31)
(0.20–0.31) (0.10–0.25) (0.08–0.33) (0.06–
0.22)
(0.13–
0.28)
Pegbovigrastim 0.33 0.3 0.12 0.07 0.06 0.2
(n = 18) (0.27–
0.41)
(0.25–0.38) (0.07–0.18) (0.04–0.14) (0.04–
0.11)
(0.14–
0.28)
P value 0.06 0.19 0.3 0.08 0.15 0.93
Back-transformed least-squares means (LSM) of blood leukocyte counts for cows treated with subcutaneous injections of pegbovigrastim or saline (control) 7 d before
expected calving and within 24 h after calving. The P-value of the LSM difference between treatment groups is shown at each time point.
https://doi.org/10.1371/journal.pone.0198701.t001
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the first injection until calving. We show that there is another significant, additive elevation in
neutrophil count on d +1, 24 h after the second injection. This increase was similar in magni-
tude to the increase at d -6 and resulted in an absolute count at d +1 approximately 10 times
that of the control group. According to Paape et al. (2002), bovine neutrophils require 10 to 14
d to fully mature from a myeloblast to a mature neutrophil in bone marrow [12]. In marrow,
maturation pools contain metamyelocytes and band cells, while storage pools contain band
cells and mature neutrophils [13]. Naturally in a cow, neutrophils in storage pools appear in
circulation after 7 d, where they have a half-life of about 9 h [12, 13]. The rapid increase in cir-
culating neutrophil count following pegbovigrastim injection is hypothesized to result from
the stimulated release of neutrophils from storage pools in bone marrow, containing both
band cells and mature neutrophils. In treated cows, 5% of neutrophils in circulation were band
cells, but no band cells were found in control cows, suggesting that pegbovigrastim stimulates
the release of both immature and mature storage pools, but primarily the latter. The speed and
magnitude of the observed increases in neutrophil counts indicate that there is a considerable
reserve of mature and band cells in the bone marrow of transition dairy cows.
There is a substantial transient increase in circulating cortisol concentrations at parturition
which causes down-regulation of expression of L-selectin on neutrophils, resulting in a release
of marginated neutrophils to circulation [14], which would be expected to increase counts in
circulation. However, consistent with other studies, in control cows, there was a slight decrease
in neutrophil count immediately following parturition, consistent with mature neutrophils
leaving circulation and migrating to sites of inflammation or infection, likely the uterus and
Fig 1. Effect of pegbovigrastim treatment on circulating neutrophil count in dairy cattle. Back-transformed least-squares means and 95% confidence intervals of
circulating blood neutrophil count (×109/L) for cows treated with 2 subcutaneous injections of pegbovigrastim (n = 18) (solid line) or saline (n = 16) (dashed line) at d -7
and d 0. Day -7 was relative to expected calving, with the actual mean interval = 6.7 ± 1.9 d. Asterisks indicate significant differences (P< 0.05) between pegbovigrastim
and saline groups.
https://doi.org/10.1371/journal.pone.0198701.g001
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udder [15]. The rates of decrease in circulating neutrophil counts after injection of pegbovi-
grastim were lower than would be expected based on the reported half-life of neutrophils [12],
which is consistent with the combined effects of the treatment to provide ongoing stimulation
of maturation and release, as well as to inhibit apoptosis of neutrophils [16].
Because the pegbovigrastim group had a significantly greater number of circulating
mature neutrophils after parturition, cows may be better equipped to respond to pathogens,
consistent with the lower incidence of clinical mastitis reported in clinical trials [9, 10]. At 7
d postpartum, there was still a significant difference between treatment groups, but not at 21
d. This provides the cow with an elevated immune capacity throughout the first 1 to 2 weeks
of lactation when the risk of mastitis and reproductive disease is high. Our results regarding
neutrophil count are consistent with previous studies. Others reported immediate increases
in neutrophil count following the first injection [7, 9, 10] or second injection [6], similar in
magnitude to those found in the current study. However, until now these responses have not
been compared to the neutrophil count at the time of injections. Kimura et al. [6] also ana-
lyzed band cell counts and found very few band cells present in control cows, and a signifi-
cantly elevated number of band cells in treated cows, especially in response to the second
injection. Our results suggest that the responses to pegbovigrastim do not deplete storage
pools of mature neutrophils because the response to the second injection was of the same
absolute magnitude as the first, and the great majority of these cells were segmented
neutrophils.
Basophils, eosinophils, and monocytes, like neutrophils, are all derived from myeloblasts,
but their differentiation is directed by growth factors other than G-CSF. The lack of effect of
treatment on basophil and monocyte counts shows that pegbovigrastim does not influence
their circulating levels. Eosinophil counts were affected by treatment, but the magnitude of
effect was minute and the differences in counts were not considered biologically important.
Lymphocytes are derived from lymphoid progenitors and should therefore not be affected
by G-CSF. However, treatment did have a significant effect on lymphocyte count at d -6,
although counts were broadly stable over time for both treatment groups, and it is unclear if
this transient difference is of biological importance. In contrast to this result, McDougall et al.
(2017), reported a substantial response to treatment in both monocyte and lymphocyte counts
[7].
Conclusions
We conclude that injection of pegbovigrastim triggers a prompt and sustained increase in cir-
culating neutrophil count in periparturient dairy cows. The injection of pegbovigrastim one
week prior to the expected calving date triggers a rapid increase in neutrophil count. There
was an additive increase following the second injection. The contribution of approximately 5%
band cells to the responses in pegbovigrastim-treated cows demonstrates that this rapid
increase is most likely a release from bone marrow storage pools instead of maturative pools,
but that the storage pool reserve is not depleted by pegbovigrastim. We encourage additional
large-scale randomized controlled trials to confirm the effects of pegbovigrastim on the risk of
reproductive and infectious disease in dairy cows during the transition period.
Supporting information
S1 Dataset. Dataset for the effects of pegbovigrastim on circulating leukocyte counts in
periparturient dairy cattle.
(CSV)
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